Allogene Therapeutics Inc. (ALLO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Allogene Therapeutics Inc... (ALLO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.88

-0.04 (-2.08%)

At close: Jan 15, 2025, 11:53 AM

undefined% (undefined)

Bid	1.87
Market Cap	393.13M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.55
PE Ratio (ttm)	-1.21
Forward PE	n/a
Analyst	Buy

Ask	1.88
Volume	1,239,006
Avg. Volume (20D)	2,653,245
Open	2.00
Previous Close	1.92
Day's Range	1.87 - 2.10
52-Week Range	1.78 - 5.78
Beta	undefined

About ALLO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 11, 2018

Employees 232

Stock Exchange NASDAQ

Ticker Symbol ALLO

Website https://www.allogene.com

Analyst Forecast

According to 9 analyst ratings, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 380.00% from the latest price.

Buy 77.78%

Hold 11.11%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Allogene Therapeutics Inc. is scheduled to release its earnings on Mar 13, 2025, during market hours.
Analysts project revenue of $12.11K, reflecting a -42.33% YoY shrinking and earnings per share of -0.18, making a -64.71% decrease YoY.

Why Price Moved

2 months ago · Source

+4.48%

Allogene Therapeutics shares are trading higher af... Unlock content with Pro Subscription

8 months ago · Source

+5.07%

Allogene Therapeutics shares are trading higher after the company reported Q1 financial results.

News

2 weeks ago · zacks.com

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.

2 weeks ago · zacks.com

Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?

Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 weeks ago · zacks.com

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.

1 month ago · zacks.com

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?

The dip in ALLO's share price can be attributed to strategic changes in its pipeline, which delayed bringing its lead drug to market by at least two years.

1 month ago · zacks.com

Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why

Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Allogene's Q3 Loss Narrower Than Expected, Sales Nil

ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.

2 months ago · seekingalpha.com

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affair and Brand Strategy Officer David...

2 months ago · zacks.com

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know

Allogene Therapeutics (ALLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.